Trials / Completed
CompletedNCT00325468
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 162 | AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2011-03-28
- Completion
- 2012-08-02
- First posted
- 2006-05-12
- Last updated
- 2017-08-01
- Results posted
- 2013-07-30
Source: ClinicalTrials.gov record NCT00325468. Inclusion in this directory is not an endorsement.